ANI Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- ANI Pharmaceuticals Inc.
- Former names
- Biosante Pharmaceuticals Inc BEN Abraham Technologies Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ANIP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001023024
- EIN
- 58-2301143
Board of directors
-
Antonio R. Pera · DirectorSince 2023
-
David Nash · DirectorSince 2023
-
Henry O. Gosebruch · DirectorSince 2026
-
Jeanne Thoma · DirectorSince 2023
-
Matthew J. Leonard · DirectorSince 2023
-
Muthusamy Shanmugam · Director · HEAD OF R&D, COO-NOVITIUM OPSSince 2023
-
Nikhil Lalwani · Director · PRESIDENT & CEOSince 2023
-
Patrick D. Walsh · DirectorSince 2023
-
Renee P. Tannenbaum · DirectorSince 2023
-
Thomas Haughey · DirectorSince 2023
Chief executives
Nikhil Lalwani
· PRESIDENT & CEO
Dates unknown
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.7%
-
97.8%
-
98.9%
-
99.7%
-
99.9%
Board connections
2 of this board's directors also sit on 2 other boards.
- via Renee P. Tannenbaum
- via Henry O. Gosebruch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $14,870,537
- 47 sales by 12 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Nikhil Lalwani Director, Officer (PRESIDENT & CEO) | Open-market sale | −5,400 | $71.00 | $383,400 |
| Sep 14, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $70.79 | $35,395 |
| Sep 11, 2026 | Jeanne Thoma Director | Open-market sale | −1,000 | $71.53 | $71,530 |
| Aug 31, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $72.80 | $207,480 |
| Aug 25, 2026 | Nikhil Lalwani Director, Officer (PRESIDENT & CEO) | Open-market sale | −5,400 | $74.30 | $401,220 |
| Aug 19, 2026 | Henry O. Gosebruch Director | Grant or award | +6,662 | — | — |
| Aug 13, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $75.48 | $37,740 |
| Aug 10, 2026 | Gutwerg Ori Officer (SVP, GENERICS) | Open-market sale | −3,162 | $77.00 | $243,474 |
| Jul 29, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $81.36 | $231,876 |
| Jul 18, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Shares withheld for tax | −2,466 | $79.20 | $195,307 |
| Jul 13, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $81.84 | $40,920 |
| Jul 2, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Option exercise | +3,313 | $49.51 | $164,027 |
| Jul 2, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −3,313 | $86.00 | $284,918 |
| Jun 29, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $84.12 | $239,742 |
| Jun 12, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $82.03 | $41,015 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.